Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells

Endocrine-Related Cancer

Volumn 19, Issue 3, 2012, Pages 447-456

  Klubo Gwiezdzinska, Joanna ^b   Jensen, Kirk ^a   Costello, John ^a   Patel, Aneeta ^a   Hoperia, Victoria ^c   Bauer, Andrew ^a   Burman, Kenneth D ^b   Wartofsky, Leonard ^b   Vasko, Vasyl ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c Transplantation of Endocrine Organs and Tissues   (Ukraine)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; CYCLIN D1; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B;

ANOIKIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTICELLULAR SPHEROID; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA;

ANOIKIS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; METFORMIN; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84862684484     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0046     Document Type: Article

References (35)

1. Astrinidis A & Henske EP 2005 Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24 7475-7481. (doi:10.1038/sj.onc.1209090)
2. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y & Bost F 2008 The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27 3576-3586. (doi:10.1038/sj.onc.1211024)
3. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF & Bost F 2010 Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Molecular Cancer Therapeutics 9 1092-1099. (doi:10.1158/1535-7163.MCT-09-1186)
4. Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI &Busaidy NL 2010 Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. Journal of Clinical Endocrinology and Metabolism 95 2588-2595. (doi:10.1210/jc.2009-1923)
5. Chen G, Xu S, Renko K & Derwahl M 2012 Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. Journal of Clinical Endocrinology and Metabolism [in press]. (doi:2012/01/20/jc.2011-1754.long)
6. Costanzo-Garvey DL, Pfluger PT, Dougherty MK, Stock JL, Boehm M, Chaika O, Fernandez MR, Fisher K, Kortum RL, Hong EG et al. 2009 KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metabolism 10 366-378. (doi:10.1016/j.cmet.2009.09.010)
7. Dell'Aglio DM, Perino LJ, Kazzi Z, Abramson J, Schwartz MD & Morgan BW 2009 Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus non-survivors: a systematic review of the literature. Annals of Emergency Medicine 54 818-823. (doi:10.1016/j. annemergmed.2009.04.023)
8. Dowling RJ, Zakikhani M, Fantus IG, Pollak M &Sonenberg N 2007 Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Research 67 10804-10812. (doi:10.1158/0008-5472.CAN-07-2310)
9. Drosten M, Hilken G, Bockmann M, Rodicker F, Mise N, Cranston AN, Dahmen U, Ponder BA & Putzer BM 2004 Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Journal of the National Cancer Institute 96 1231-1239. (doi:10.1093/jnci/djh226)
10. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M & Leverve X 2000 Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. Journal of Biological Chemistry 275 223-228. (doi:10.1074/jbc.275.1.223)
11. Faggiano A, Ramundo V, Dicitore A, Castiglioni S, Borghi MO, Severino R, Ferolla P, Crino L, Abbruzzese A, Sperlongano P et al. 2011 Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. Journal of Cellular and Molecular Medicine [in press]. (doi:10.1111/j.15824934.2011. 01438.x)
12. Fukazawa H, Noguchi K, Murakami Y & Uehara Y 2002 Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Molecular Cancer Therapeutics 1 303-309.
13. Goldstein NB, Johannes WU, Gadeliya AV, Green MR, Fujita M, Norris DA & Shellman YG 2009 Active N-Ras and B-Raf inhibit anoikis by downregulating Bim expression in melanocytic cells. Journal of Investigative Dermatology 129 432-437. (doi:10.1038/jid.2008.227)
14. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN & Bruchim I 2008 In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology 110 246-250. (doi:10.1016/j.ygyno.2008.04.008)
15. de Groot JW, Links TP, Plukker JT, Lips CJ & Hofstra RM 2006 RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocrine Reviews 27 535-560. (doi:10.1210/er.2006-0017)
16. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB & Shimon I 2010 The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Molecular and Cellular Endocrinology 315 87-94. (doi:10.1016/j.mce.2009.09.027)
17. Guertin DA & Sabatini DM2007 Defining the role of mTOR in cancer. Cancer Cell 12 9-22. (doi:10.1016/j.ccr.2007.05.008)
18. Hundahl SA, Fleming ID, Fremgen AM& Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83 2638-2648. (doi:10.1002/(SICI)1097-0142 (19981215)83:12〈2638::AID-CNCR31〉3.0.CO;2-1)
19. Jensen K, PatelA, Klubo-Gwiezdzinska J, Bauer A&Vasko V 2011 Inhibition of gap junction transfer sensitizes thyroid cancer cells to anoikis. Endocrine-Related Cancer 18 613-626. (doi:10.1530/ERC-10-0289)
20. Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV et al. 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of Clinical Oncology 28 2323-2330. (doi:10.1200/JCO.2009.25.0068)
21. Lanzi C, Cassinelli G, Nicolini V & Zunino F 2009 Targeting RET for thyroid cancer therapy. Biochemical Pharmacology 77 297-309. (doi:10.1016/j.bcp.2008.10.033)
22. Luo Z, Zang M & Guo W 2010 AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncology 6 457-470. (doi:10.2217/fon.09.174)
23. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C &Menendez JA 2010 Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 9 1057-1064. (doi:10.4161/cc.9.6.10994)
24. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L et al. 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clinical Endocrinology 48 265-273. (doi:10.1046/j.1365-2265.1998. 00392.x)
25. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC & Rubello D 2007 Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. European Journal of Surgical Oncology 33 493-497. (doi:10.1016/j.ejso. 2006.10.021)
26. Rapa I, Saggiorato E, Giachino D, Palestini N, Orlandi F, Papotti M & Volante M 2011 Mammalian target of rapamycin pathway activation is associated to RET mutation status in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 96 2146-2153. (doi:10.1210/jc.2010-2655)
27. Segouffin-Cariou C & Billaud M 2000 Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. Journal of Biological Chemistry 275 3568-3576. (doi:10.1074/jbc.275.5.3568)
28. Shaw RJ 2009 LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiologica 196 65-80. (doi:10.1111/j.1748-1716. 2009.01972.x)
29. Shaw RJ & Cantley LC 2006 Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 424-430. (doi:10.1038/nature04869)
30. Sonenberg N & Gingras AC 1998 The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Current Opinion in Cell Biology 10 268-275. (doi:10.1016/S0955-0674(98)80150-6)
31. Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A et al. 2007 Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. PNAS 104 2803-2808. (doi:10.1073/pnas.0610733104)
32. Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud L, Leclerc S et al. 1994 Inhibition of cyclin-dependent kinases by purine analogues. European Journal of Biochemistry 224 771-786. (doi:10.1111/j.1432-1033.1994.00771.x)
33. Wullschleger S, Loewith R & Hall MN 2006 TOR signaling in growth and metabolism. Cell 124 471-484. (doi:10.1016/j.cell.2006.01.016)
34. Zhuang Y & Miskimins WK 2008 Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. Journal of Molecular Signaling 3 18. (doi:10.1186/1750-2187-3-18)
35. Zugasti O, Rul W, Roux P, Peyssonnaux C, Eychene A, Franke TF, Fort P & Hibner U 2001 Raf-MEK-Erk cascade in anoikis is controlled by Rac1 and Cdc42 via Akt. Molecular and Cellular Biology 21 6706-6717. (doi:10.1128/MCB.21. 19.6706-6717.2001)